In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) submitted feedback on ICER's assessment of treatments for vasomotor symptoms associated with menopause
The letter criticizes ICER for using flawed patient-reported outcomes tools to generate utility values that are not representative of the patient experience. PIPC also takes issue with the model for being overly simplistic and conducted too early without the full range of data.
"We continue to be concerned about ICER’s reliance on quality-adjusted life years (QALYs) to value treatments, a method that perpetuates not only devaluation of people living with disabilities and chronic conditions but also over-reliance on simplistic modeling and flawed utilities," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to pause this assessment until more full data is available and to amend its methodologies more broadly to better reflect the patient experience."
"We continue to be concerned about ICER’s reliance on quality-adjusted life years (QALYs) to value treatments, a method that perpetuates not only devaluation of people living with disabilities and chronic conditions but also over-reliance on simplistic modeling and flawed utilities," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to pause this assessment until more full data is available and to amend its methodologies more broadly to better reflect the patient experience."
| icer_menopause_final_for_submission.pdf |